US7230000B1
(en)
|
1999-10-27 |
2007-06-12 |
Cytokinetics, Incorporated |
Methods and compositions utilizing quinazolinones
|
US7671200B2
(en)
|
1999-10-27 |
2010-03-02 |
Cytokinetics, Inc. |
Quinazolinone KSP inhibitors
|
US6924376B2
(en)
|
2002-04-17 |
2005-08-02 |
Cytokinetics, Inc. |
Compounds, compositions and methods
|
AU2003223786A1
(en)
|
2002-05-09 |
2003-11-11 |
Cytokinetics, Inc. |
Compounds, methods and compositions
|
AU2003252025A1
(en)
|
2002-07-17 |
2004-02-02 |
Cytokinetics, Inc. |
Compounds, compositions, and methods
|
WO2004018058A2
(en)
*
|
2002-08-21 |
2004-03-04 |
Cytokinetics, Inc. |
Compounds, compositions, and methods
|
WO2004078758A1
(en)
*
|
2003-03-07 |
2004-09-16 |
Astrazeneca Ab |
Novel fused heterocycles and uses thereof
|
US20040242566A1
(en)
*
|
2003-03-25 |
2004-12-02 |
Syrrx, Inc. |
Dipeptidyl peptidase inhibitors
|
US7345046B2
(en)
|
2003-05-30 |
2008-03-18 |
Chiron Corporation |
Heteroaryl-fused pyrimidinyl compounds as anticancer agents
|
CA2533889A1
(en)
*
|
2003-08-15 |
2005-03-03 |
Merck & Co., Inc. |
Mitotic kinesin inhibitors
|
SI1689724T1
(sl)
*
|
2003-11-25 |
2012-04-30 |
Novartis Ag |
Spojine kinazolinona kot sredstva proti raku
|
DK1753723T3
(da)
|
2004-05-21 |
2008-10-20 |
Novartis Vaccines & Diagnostic |
Substituerede quinolinderivater som mitotiske kinesininhibitorer
|
US7576221B2
(en)
|
2004-06-18 |
2009-08-18 |
Novartis Vaccines And Diagnostics, Inc. |
Substituted imidazole derivatives
|
DE602005023730D1
(de)
*
|
2004-07-01 |
2010-11-04 |
Merck Sharp & Dohme |
Inhibitoren von mitotischem kinesin
|
RU2447077C2
(ru)
|
2004-08-18 |
2012-04-10 |
Астразенека Аб |
Энантиомеры выбранных конденсированных пиримидинов и их применение для лечения и предотвращения злокачественного новообразования
|
JP2008517057A
(ja)
|
2004-10-19 |
2008-05-22 |
ノバルティス ヴァクシンズ アンド ダイアグノスティクス, インコーポレイテッド |
インドールおよびベンゾイミダゾール誘導体
|
US20080102068A1
(en)
*
|
2005-01-19 |
2008-05-01 |
Coleman Paul J |
Mitotic Kinesin Inhibitors
|
MX2007010972A
(es)
*
|
2005-03-09 |
2007-09-19 |
Schering Corp |
Compuestos tieno[2,3-b]piridina y tiazolo[5,4-b]piridina para inhibir la actividad de quinesina de proteina de quinesina del huso acromatico.
|
MX2007010973A
(es)
*
|
2005-03-09 |
2007-09-19 |
Schering Corp |
Compuestos para inhibir la actividad de cinesina de ksp.
|
US7608643B2
(en)
|
2005-03-09 |
2009-10-27 |
Schering Corporation |
Compounds for inhibiting KSP kinesin activity
|
ATE550019T1
(de)
|
2005-05-17 |
2012-04-15 |
Merck Sharp & Dohme |
Cis-4-ä(4-chlorophenyl)sulfonylü-4-(2,5- difluorophenyl)cyclohexanepropansäure zur behandlug von krebs
|
US20070213305A1
(en)
*
|
2005-11-02 |
2007-09-13 |
Cytovia, Inc. |
N-alkyl-N-aryl-thienopyrimidin-4-amines and analogs as activators of caspases and inducers of apoptosis and the use thereof
|
WO2007056208A2
(en)
*
|
2005-11-02 |
2007-05-18 |
Cytovia, Inc. |
N-arylalkyl-thienopyrimidin-4-amines and analogs as activators of caspases and inducers of apoptosis and the use thereof
|
US20070099877A1
(en)
*
|
2005-11-02 |
2007-05-03 |
Cytovia, Inc. |
N-aryl-thienopyrimidin-4-amines and analogs as activators of caspases and inducers of apoptosis and the use thereof
|
GB0603041D0
(en)
|
2006-02-15 |
2006-03-29 |
Angeletti P Ist Richerche Bio |
Therapeutic compounds
|
CA2655159C
(en)
|
2006-06-28 |
2014-12-30 |
Amgen Inc. |
Glycine transporter-1 inhibitors
|
US20080051380A1
(en)
|
2006-08-25 |
2008-02-28 |
Auerbach Alan H |
Methods and compositions for treating cancer
|
CA2664113C
(en)
|
2006-09-22 |
2013-05-28 |
Merck & Co., Inc. |
Use of platencin and platensimycin as fatty acid synthesis inhibitors to treat obesity, diabetes and cancer
|
US20110218176A1
(en)
|
2006-11-01 |
2011-09-08 |
Barbara Brooke Jennings-Spring |
Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development
|
MX2009005071A
(es)
|
2006-11-13 |
2009-05-25 |
Novartis Ag |
Compuestos de pirazol y triazol sustituidos como inhibidores de ksp.
|
JP5313909B2
(ja)
*
|
2006-11-13 |
2013-10-09 |
アイコス コーポレイション |
炎症性疾患および癌の処置のためのチエノピリミジノン
|
US7820646B2
(en)
|
2007-01-05 |
2010-10-26 |
Novartis Vaccines And Diagnostics, Inc. |
Cyclized derivatives as Eg-5 inhibitors
|
DK2805945T3
(da)
|
2007-01-10 |
2019-07-15 |
Msd Italia Srl |
Amid-substituerede indazoler som poly(adp-ribose)polymerase- (parp) hæmmere
|
MX2009009304A
(es)
|
2007-03-01 |
2009-11-18 |
Novartis Ag |
Inhibidores de cinasa pim y metodos para su uso.
|
WO2008144062A1
(en)
|
2007-05-21 |
2008-11-27 |
Novartis Ag |
Csf-1r inhibitors, compositions, and methods of use
|
EP2170076B1
(de)
|
2007-06-27 |
2016-05-18 |
Merck Sharp & Dohme Corp. |
4-carboxybenzylamino-derivate als histondeacetylase-hemmer
|
US8691825B2
(en)
|
2009-04-01 |
2014-04-08 |
Merck Sharp & Dohme Corp. |
Inhibitors of AKT activity
|
US8940752B2
(en)
|
2009-06-29 |
2015-01-27 |
Incyte Corporation |
Pyrimidinones as PI3K inhibitors
|
CA2768843A1
(en)
|
2009-07-21 |
2011-01-27 |
Gilead Calistoga Llc |
Treatment of liver disorders with pi3k inhibitors
|
UA109417C2
(uk)
|
2009-10-14 |
2015-08-25 |
Мерк Шарп Енд Доме Корп. |
ЗАМІЩЕНІ ПІПЕРИДИНИ, ЯКІ ПІДВИЩУЮТЬ АКТИВНІСТЬ p53, І ЇХ ЗАСТОСУВАННЯ
|
WO2011075643A1
(en)
|
2009-12-18 |
2011-06-23 |
Incyte Corporation |
Substituted heteroaryl fused derivatives as pi3k inhibitors
|
EP2558463A1
(de)
|
2010-04-14 |
2013-02-20 |
Incyte Corporation |
Kondensierte derivate als i3-hemmer
|
US9062055B2
(en)
|
2010-06-21 |
2015-06-23 |
Incyte Corporation |
Fused pyrrole derivatives as PI3K inhibitors
|
EP2584903B1
(de)
|
2010-06-24 |
2018-10-24 |
Merck Sharp & Dohme Corp. |
Neue heterozyklische verbindungen als erk-hemmer
|
EP3330377A1
(de)
|
2010-08-02 |
2018-06-06 |
Sirna Therapeutics, Inc. |
Durch rna-interferenz vermittelte hemmung der catenin (cadherin-assoziiertes protein)-beta-1 (ctnnb1)- genexpression mittels kurzer interferierender nukleinsäuren (sina)
|
KR102072631B1
(ko)
|
2010-08-17 |
2020-02-03 |
시르나 쎄러퓨틱스 인코퍼레이티드 |
짧은 간섭 핵산 (siNA)을 사용한 B형 간염 바이러스 (HBV) 유전자 발현의 RNA 간섭 매개 억제
|
EP2608669B1
(de)
|
2010-08-23 |
2016-06-22 |
Merck Sharp & Dohme Corp. |
Neue pyrazolo-[1,5-a-]pyrimidinderivate als mtor-hemmer
|
EP2613782B1
(de)
|
2010-09-01 |
2016-11-02 |
Merck Sharp & Dohme Corp. |
Indazolderivate als erk-hemmer
|
US9260471B2
(en)
|
2010-10-29 |
2016-02-16 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of gene expression using short interfering nucleic acids (siNA)
|
EP2455456A1
(de)
|
2010-11-22 |
2012-05-23 |
Institut Curie |
Verwendung von Kinesininhibitoren bei der Behandlung von HIV-Infektion und Verfahren zu deren Abtastung
|
TW201249844A
(en)
|
2010-12-20 |
2012-12-16 |
Incyte Corp |
N-(1-(substituted-phenyl)ethyl)-9H-purin-6-amines as PI3K inhibitors
|
WO2012087772A1
(en)
|
2010-12-21 |
2012-06-28 |
Schering Corporation |
Indazole derivatives useful as erk inhibitors
|
US9108984B2
(en)
|
2011-03-14 |
2015-08-18 |
Incyte Corporation |
Substituted diamino-pyrimidine and diamino-pyridine derivatives as PI3K inhibitors
|
US9126948B2
(en)
|
2011-03-25 |
2015-09-08 |
Incyte Holdings Corporation |
Pyrimidine-4,6-diamine derivatives as PI3K inhibitors
|
CN103732592A
(zh)
|
2011-04-21 |
2014-04-16 |
默沙东公司 |
胰岛素样生长因子-1受体抑制剂
|
CA2846652C
(en)
|
2011-09-02 |
2019-11-05 |
Incyte Corporation |
Heterocyclylamines as pi3k inhibitors
|
US9023865B2
(en)
|
2011-10-27 |
2015-05-05 |
Merck Sharp & Dohme Corp. |
Compounds that are ERK inhibitors
|
AR090548A1
(es)
|
2012-04-02 |
2014-11-19 |
Incyte Corp |
Azaheterociclobencilaminas biciclicas como inhibidores de pi3k
|
EP3358013B1
(de)
|
2012-05-02 |
2020-06-24 |
Sirna Therapeutics, Inc. |
Sina-zusammensetzungen
|
US9233979B2
(en)
|
2012-09-28 |
2016-01-12 |
Merck Sharp & Dohme Corp. |
Compounds that are ERK inhibitors
|
CA2892361A1
(en)
|
2012-11-28 |
2014-06-05 |
Merck Sharp & Dohme Corp. |
Use of a wee1 inhibitor for treating a cancer characterized by low pkmyt1 expression levels
|
WO2014100065A1
(en)
|
2012-12-20 |
2014-06-26 |
Merck Sharp & Dohme Corp. |
Substituted imidazopyridines as hdm2 inhibitors
|
US9540377B2
(en)
|
2013-01-30 |
2017-01-10 |
Merck Sharp & Dohme Corp. |
2,6,7,8 substituted purines as HDM2 inhibitors
|
US20160194368A1
(en)
|
2013-09-03 |
2016-07-07 |
Moderna Therapeutics, Inc. |
Circular polynucleotides
|
WO2015191677A1
(en)
|
2014-06-11 |
2015-12-17 |
Incyte Corporation |
Bicyclic heteroarylaminoalkyl phenyl derivatives as pi3k inhibitors
|
JO3589B1
(ar)
|
2014-08-06 |
2020-07-05 |
Novartis Ag |
مثبطات كيناز البروتين c وطرق استخداماتها
|
MY187502A
(en)
|
2015-02-27 |
2021-09-24 |
Incyte Corp |
Salts of pi3k inhibitor and processes for their preparation
|
US9988401B2
(en)
|
2015-05-11 |
2018-06-05 |
Incyte Corporation |
Crystalline forms of a PI3K inhibitor
|
US9732097B2
(en)
|
2015-05-11 |
2017-08-15 |
Incyte Corporation |
Process for the synthesis of a phosphoinositide 3-kinase inhibitor
|
EP3394056B1
(de)
|
2015-12-22 |
2021-04-14 |
Shy Therapeutics LLC |
Verbindungen zur behandlung von krebs und entzündungskrankheiten
|
JOP20190055A1
(ar)
|
2016-09-26 |
2019-03-24 |
Merck Sharp & Dohme |
أجسام مضادة ضد cd27
|
KR20190140454A
(ko)
|
2017-04-13 |
2019-12-19 |
아두로 바이오테크 홀딩스, 유럽 비.브이. |
항-sirp 알파 항체
|
US10588894B2
(en)
|
2017-06-21 |
2020-03-17 |
SHY Therapeutics LLC |
Compounds that interact with the Ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease
|
EP3706742B1
(de)
|
2017-11-08 |
2023-03-15 |
Merck Sharp & Dohme LLC |
Prmt5-inhibitoren
|
WO2019148412A1
(en)
|
2018-02-01 |
2019-08-08 |
Merck Sharp & Dohme Corp. |
Anti-pd-1/lag3 bispecific antibodies
|
EP3833668A4
(de)
|
2018-08-07 |
2022-05-11 |
Merck Sharp & Dohme Corp. |
Prmt5-inhibitoren
|
US20210309688A1
(en)
|
2018-08-07 |
2021-10-07 |
Merck Sharp & Dohme Corp. |
Prmt5 inhibitors
|
BR112022012032A2
(pt)
|
2019-12-17 |
2022-09-06 |
Merck Sharp & Dohme Llc |
Inibidores de prmt5
|
US11932656B1
(en)
|
2023-10-06 |
2024-03-19 |
King Faisal University |
Thieno[2,3-d]pyrimidines as COX-2 inhibitors
|